Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure

Zhang Jin-guo; Yang Na; He Hua; Wei Guang-he; Gao Dong-sheng; Wang Xiao-li; Wang Xue-zhong; Song Guang-yao

doi:10.1007/BF02836502

Your Location：

Home >

Browse articles >

Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure

Updated：2021-08-27

- Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure
- Chinese Journal of Integrative Medicine Vol. 11, Issue 3, Pages: 187-190(2005)
- Affiliations：
  
  1. Department of Cardiology, Affiliated Hospital of Jining Medical College,Shandong
  2. Department of Cardiology, People’s Hospital of Hebei Province, Shijiazhang
- Author bio：
- Funds：
- DOI：10.1007/BF02836502
  CLC：
- Published：2005，
Scan for full text
Jin-guo, Z., Na, Y., Hua, H. et al. Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure., Chin. J. Integr. Med. 11, 187–190 (2005). https://doi.org/10.1007/BF02836502

Zhang Jin-guo, Yang Na, He Hua, et al. Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure. [J]. Chinese Journal of Integrative Medicine 11(3):187-190(2005)
Jin-guo, Z., Na, Y., Hua, H. et al. Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure., Chin. J. Integr. Med. 11, 187–190 (2005). https://doi.org/10.1007/BF02836502 DOI：

Zhang Jin-guo, Yang Na, He Hua, et al. Effect of Astragalus injection on plasma levels of apoptosis-related factors in aged patients with chronic heart failure. [J]. Chinese Journal of Integrative Medicine 11(3):187-190(2005) DOI： 10.1007/BF02836502.

摘要

Objective: To investigate the effect of Astragalus injection (AI) on plasma levels of apoptosis-related factors in aged patients with chronic heart failure (CHF).Methods: Seventy-two CHF patients were randomly divided into the AI group (36 cases) treated with AI and the control group (36 cases) treated with conventional treatment. Plasma levels of soluble Fas (sFas)

soluble Fas ligand (sFasL)

tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assays (ELISA) with monoclonal anti-human antibodies. Besides

New York Heart Association (NYHA) grading was assessed according to improved symptoms and left ventricular end-diastolic volume (LVEDV)

left ventricular end-systolic volume (LVESV) and left ventricular ejection fraction (LVEF) were assessed by echocardiogram after 4 weeks of treatment.Results: After 4 weeks of treatment

NYHA grading was markedly improved in the two groups

but it was significantly better in AI group than that in the control group (P<0.05). As compared with the control group

sFas

sFasL

TNF-α and IL-6 in the AI group were obviously lower

the difference between the two groups and between before and after treatment were significant (P<0.05 orP 0.01). Moreover

in AI group

LVESV and LVEDV decreased

LVEF increased

which was significantly different than that before treatment (P<0.05)

respectively.Conclusion: AI could lower plasma levels of apoptosis-related factors

and is one of the effective drugs in improving cardiac function in the aged patients with CHF.

Abstract

soluble Fas ligand (sFasL)

tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assays (ELISA) with monoclonal anti-human antibodies. Besides

New York Heart Association (NYHA) grading was assessed according to improved symptoms and left ventricular end-diastolic volume (LVEDV)

left ventricular end-systolic volume (LVESV) and left ventricular ejection fraction (LVEF) were assessed by echocardiogram after 4 weeks of treatment.Results: After 4 weeks of treatment

NYHA grading was markedly improved in the two groups

but it was significantly better in AI group than that in the control group (P<0.05). As compared with the control group

sFas

sFasL

TNF-α and IL-6 in the AI group were obviously lower

the difference between the two groups and between before and after treatment were significant (P<0.05 orP 0.01). Moreover

in AI group

LVESV and LVEDV decreased

LVEF increased

which was significantly different than that before treatment (P<0.05)

respectively.Conclusion: AI could lower plasma levels of apoptosis-related factors

and is one of the effective drugs in improving cardiac function in the aged patients with CHF.

关键词

chronic heart failurethe agedapoptosiscytokinesAstragalus Injection

Keywords

chronic heart failurethe agedapoptosiscytokinesAstragalus Injection

references

Sasayama S, Matsumori A. Role of cytokines in the syndrome of heart failure. Intern Med 1996;35 (1): 60–63.

Kang PM, Izumo S. Apoptosis and heart failure. Circ Res 2000; 86(11): 1107–1113.

Mckee PA, Castell WP, Mcnamara PM, et al. The natural history of congestive heart failure, the Framingham study. N Engl J Med 1971;285(26): 1444–1452.

Chen QM, Tu VC. Apoptosis and heart failure: mechanisms and therapeutic implications. Am J Cardiovas Drugs 2002;2(l): 43–57.

Tsutamoto T, Wada A, Maeda K, et al. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. J Cardiac Failure 2001;7(4): 322–328.

Zhou ZL, Yu P, Lin D, et al. Study on effect of Astragalus injection in treating congestive heart failure. Chin J Integr Tradit West Med (Chin) 2001;21(10): 747–749.

Zhang JG, Gao DS, Yang N, et al. Effect of Astragalus injection on left ventricular remodeling in aged patients with acute early-stage myocardial infarction. Chin J Integr Med 2003;9(2): 104–107.

Wang GY, Guo XM. Effects of Radix Astragali on the nitric oxide, free radicals and apoptosis of thymus in aging mice. J Mudanjiang Med Coll 2004;25(4): 14–15.

Song DJ, Gu GD, Mao SY, et al. Effect of Astragalus membranaceus on spontaneously hypertensive rats. Chin Tradit Herbal Drugs 1989;20(8): 25–28.

Zhong F, Du JZ, Yu XH, et al. Effect of Astragaloside on apoptosis in viral myocarditis. J Nanhua Univ (Med ed) 2004;32(l): 17–19.

Jiang LM, Li W, Wei KL. Effects of Astragalus Injection on perforin in myocardial infiltrating cell and expression of FasL mRNA in mice with acute myocarditis. For Med (Fascicle of Pediatrics) 2003;30(2): 111–112.

Liu ZG, Xiong ZM, Yu XY. Effect of Astragalus Injection on immune function in patients with congestive heart failure. Chin J Integr Tradit West Med (Chin) 2003;23(5): 351–353.

Ruan CW, Zhang DF, Wang SS, et al, The effects of Huangqi on myocyte apoptosis and the expression of apoptosis-associated genes in rat heart with acute myocardial ischemia and reperfusion. J Tongji Univ (Med Sci) 2003;24(3): 182–184.

FULL TEXT LINK

More>

Views

370

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effect of Astragalus Injection on left ventricular remodeling in aged patients with acute early-stage myocardial infarction

Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line

Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells

The ethanol extract isolated from Weiqi Decoction (胃祺饮) induces G2/M arrest and apoptosis in AGS cells

Effects of Danshen Injection (丹参注射液) on inhibiting proliferation and inducing apoptosis through down-regulation of mutant JAK2 gene and its protein phosphorylation in human erythroid leukemic cells

Related Author

No data

Related Institution

Affiliated Hospital of Jining Medical College

Hebei Provincial People’s Hospital

Jining Medical College

Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran

Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰